SELLAS Life Sciences Group, Inc. Deferred Tax Assets, Operating Loss Carryforwards
SELLAS Life Sciences Group, Inc. (SLS) had Deferred Tax Assets, Operating Loss Carryforwards of $16.73 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $16.73M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $14.12M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $12.22M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $10.53M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $16.73M 10-K · filed 2026-03-19 | |
| 2024-12-31 | $14.12M 10-K · filed 2026-03-19 | |
| 2023-12-31 | $12.22M 10-K · filed 2025-03-20 | |
| 2022-12-31 | $10.53M 10-K · filed 2024-03-28 | |
| 2021-12-31 | $9.06M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $7.16M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $6.72M 10-K · filed 2021-03-23 | |
| 2018-12-31 | $4.46M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $1.03M 10-K · filed 2019-03-22 | |
| 2016-12-31 | $3.15M 10-K · filed 2018-04-13 | $97.17M 10-K · filed 2017-03-15 |
| 2015-12-31 | $75.22M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $53.95M 10-K/A · filed 2016-04-15 | |
| 2013-12-31 | $33.54M 8-K · filed 2015-12-04 | |
| 2012-12-31 | $23.63M 10-K · filed 2014-03-17 | |
| 2011-12-31 | $18.79M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |